JP2008545777A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545777A5
JP2008545777A5 JP2008515378A JP2008515378A JP2008545777A5 JP 2008545777 A5 JP2008545777 A5 JP 2008545777A5 JP 2008515378 A JP2008515378 A JP 2008515378A JP 2008515378 A JP2008515378 A JP 2008515378A JP 2008545777 A5 JP2008545777 A5 JP 2008545777A5
Authority
JP
Japan
Prior art keywords
chemical
acid addition
addition salt
conjugate
psychotropic drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008515378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545777A (ja
JP5284779B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2006/000666 external-priority patent/WO2006131923A2/en
Publication of JP2008545777A publication Critical patent/JP2008545777A/ja
Publication of JP2008545777A5 publication Critical patent/JP2008545777A5/ja
Application granted granted Critical
Publication of JP5284779B2 publication Critical patent/JP5284779B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008515378A 2005-06-07 2006-06-07 コンジュゲート化された向精神薬の新規な塩およびその調製方法 Expired - Fee Related JP5284779B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68785105P 2005-06-07 2005-06-07
US60/687,851 2005-06-07
US79450106P 2006-04-25 2006-04-25
US60/794,501 2006-04-25
PCT/IL2006/000666 WO2006131923A2 (en) 2005-06-07 2006-06-07 Novel salts of conjugated psychotropic drugs and processes of preparing same

Publications (3)

Publication Number Publication Date
JP2008545777A JP2008545777A (ja) 2008-12-18
JP2008545777A5 true JP2008545777A5 (enExample) 2009-07-16
JP5284779B2 JP5284779B2 (ja) 2013-09-11

Family

ID=37033348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008515378A Expired - Fee Related JP5284779B2 (ja) 2005-06-07 2006-06-07 コンジュゲート化された向精神薬の新規な塩およびその調製方法

Country Status (8)

Country Link
US (1) US20090298814A1 (enExample)
EP (1) EP1888120B1 (enExample)
JP (1) JP5284779B2 (enExample)
AU (1) AU2006256369B2 (enExample)
CA (1) CA2610838A1 (enExample)
ES (1) ES2400772T3 (enExample)
MX (1) MX2007015511A (enExample)
WO (1) WO2006131923A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
EP2029566B1 (en) 2006-06-22 2011-04-27 Ramot, at Tel Aviv University Ltd. Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
US9278947B2 (en) 2006-06-22 2016-03-08 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
MX2009000641A (es) * 2006-07-17 2009-02-12 Univ Ramot Conjugados que comprenden un farmaco sicotropico o un agonista de gaba y un acido organico y su uso en el tratamiento del dolor y otros desordenes del cns.
EP2252578B1 (en) 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
MX2012006566A (es) 2009-12-09 2012-11-29 Univ Ramot Metodo para mejorar las funciones cognoscitivas.
CA2789654A1 (en) * 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2944053A (en) * 1960-07-05 Uiiilcu
US2914528A (en) * 1958-04-16 1959-11-24 Smith Kline French Lab Substituted phenothiazinyl trifluoro-methyl sulfones
NL105973C (enExample) * 1957-09-11 1900-01-01
US2969358A (en) * 1958-12-08 1961-01-24 Searle & Co 2-chloro-10-phenothiazinecarbonylpiperazines
US3956492A (en) * 1972-07-12 1976-05-11 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing a 3-(amino-methylene)-5-phenyl-1,4-benzodiazepin-2-one and method of use
GB1460713A (en) * 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US3978216A (en) * 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US3947579A (en) * 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3956493A (en) * 1974-10-21 1976-05-11 E. R. Squibb & Sons, Inc. Long acting tranquilizing agent
GB1540842A (en) * 1976-08-25 1979-02-14 Kefalas As Phenothiazines
US5525727A (en) * 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US4629691A (en) * 1983-08-01 1986-12-16 Syntex (U.S.A.) Inc. Tricyclic antidepressant conjugates with antigens and enzymes
US5051448A (en) * 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
EP0211905B1 (en) * 1985-02-15 1990-10-03 The Broken Hill Proprietary Company Limited Classification of steel
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5780590A (en) * 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
EP0730578A4 (en) * 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING INDOLYL GROUPS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONES
US5534522A (en) * 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
WO1997002819A1 (en) * 1995-07-13 1997-01-30 Anormed Inc, 2-[2-(dimethylamino)ethyl]-8,8-dipropyl-2-azaspiro[4.5]decane dimaleate
CA2162532C (en) * 1995-11-09 2001-01-30 Dana J. Vanier Gemstone registration system
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
US5966673A (en) * 1997-01-10 1999-10-12 Diamond Technologies, Inc. System and method for computerized evaluation of gemstones
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6020954A (en) * 1997-12-18 2000-02-01 Imagestatistics, Inc. Method and associated apparatus for the standardized grading of gemstones
US5983238A (en) * 1997-12-26 1999-11-09 Diamond Id Gemstons identification tracking and recovery system
US20010024532A1 (en) * 1998-09-21 2001-09-27 Malnekoff Peter J. Automated gemstone evaluation system
US6304853B1 (en) * 1998-09-21 2001-10-16 Peter J. Malnekoff Automated gemstone evaluation system
US6381510B1 (en) * 1999-11-19 2002-04-30 Eruggallery.Com Methods and apparatus for facilitating electronic commerce in area rugs
US20020021439A1 (en) * 2000-08-07 2002-02-21 Derek Priestley Colour matching system
US7251619B2 (en) * 2000-09-01 2007-07-31 Garry Ian Holloway Computer implemented method, computer program product, and system for gem evaluation
JP2005097120A (ja) * 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd 4−ヒドロキシピペリジン誘導体の非潮解性塩
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20030065586A1 (en) * 2001-07-31 2003-04-03 Shaftel Keith L. Electronic commerce product pricing and selection system and method
US20030115079A1 (en) * 2001-08-30 2003-06-19 Rapaport Martin M. Method of and system for ranking optimal values
KR20100097224A (ko) * 2001-09-27 2010-09-02 라모트 앳 텔 아비브 유니버시티 리미티드 접합된 항-정신병 약물 및 그의 용도
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
EP1500010A4 (en) * 2002-01-25 2005-04-27 Menahem Sevdermish METHOD FOR THE DIGITAL COLOR GRADING OF JEWELS AND COMMUNICATION THEREFOR
US8046274B2 (en) * 2002-01-25 2011-10-25 Menahem Sevdermish Method for digital color grading of gems and communication thereof
US20040092504A1 (en) * 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7151084B2 (en) * 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
MX2009000641A (es) * 2006-07-17 2009-02-12 Univ Ramot Conjugados que comprenden un farmaco sicotropico o un agonista de gaba y un acido organico y su uso en el tratamiento del dolor y otros desordenes del cns.
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
CA2789654A1 (en) * 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same

Similar Documents

Publication Publication Date Title
CN109769392B (zh) 苯并咪唑衍生物的酸加成盐
JP2008545777A5 (enExample)
AU2010204986B2 (en) Transdermal administration of tamsulosin
RS58335B1 (sr) Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena
JP2010530431A5 (enExample)
JP2006509749A5 (enExample)
WO2011106688A1 (en) Bis-fatty acid conjugates and their uses
JP2004519469A5 (enExample)
CA2131797A1 (en) Condensed indole derivatives as 5ht4-receptor antagonists
ES2870614T3 (es) Hemihidrato de la base libre de la N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida, métodos para su fabricación y sus usos
CN107105660A (zh) 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
HUP0100853A2 (hu) Fekély kezelésére alkalmas nitrátsók és ilyen vegyületeket tartalmazó gyógyászati készítmények
WO2005023766A1 (en) Salt of atorvastatin with metformin
TWI285110B (en) Parkinson disease therapeutic agent
JP2011503142A5 (enExample)
JPH04217915A (ja) 4−エチル−2−ヒドロキシイミノ−5−ニトロ−3−ヘキセンアミド含有製剤用の安定化剤、安定化方法及び安定化された製剤
JP2009513710A5 (enExample)
JP2008521874A5 (enExample)
HRP20161485T1 (hr) Polimorfna forma n-[4-(trifluorometil)benzil)-4-metoksibutiramida
US10874624B2 (en) Stable trientine formulations
JP2006502173A (ja) 痛みを治療するためのバニロイド受容体アンタゴニストの使用
CN114746091A (zh) D-苯丙胺化合物、组合物、以及制备和使用它们的方法
CN1678583A (zh) 氨氯地平的有机酸盐
WO2015001568A2 (en) Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
WO2005033067A1 (en) SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE